Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 114 Lung Neoplasms 83 Lymphoma 76 Head and Neck Neoplasms 76 Glioblastoma 75 Squamous Cell Carcinoma of Head and Neck 71 Breast Neoplasms 71 Rectal Neoplasms 67 Esophageal Neoplasms 63 Prostatic Neoplasms 59 Leukemia 57 Central Nervous System Neoplasms 54 Pancreatic Neoplasms 51 Precursor Cell Lymphoblastic Leukemia-Lymphoma 47 Lymphoma, Non-Hodgkin 43 Lymphoma, Large B-Cell, Diffuse 43 Hodgkin Disease 42 Lymphoma, Follicular 41 Brain Neoplasms 40 Leukemia, Lymphocytic, Chronic, B-Cell 39 Esophageal Squamous Cell Carcinoma 39 Colorectal Neoplasms 38 Burkitt Lymphoma 37 Gliosarcoma 36 Lymphoma, Large-Cell, Immunoblastic 33 Uterine Cervical Neoplasms 31 Neoplasms 31 Adenocarcinoma Of Esophagus 31 Lymphoma, Mantle-Cell 30 Lymphoma, B-Cell, Marginal Zone 29

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Muscle-Invasive Bladder Carcinoma × Radiotherapy × Clear all

NCT05203913 2024-10-04

CNN-BC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡